colon cancer news from FierceBiotech
News
A deluge of pre-ASCO data hits the market
ALSO NOTED: Curis earns $3M milestone; Lethal viral outbreak in China; and much more...
ALSO NOTED: FDA nixes Avastin for breast cancer; P&G reveals Phase II UC data;and much more...
SPOTLIGHT: Erbitux ok'd as front-line colon cancer drug
SPOTLIGHT: Breast cancer therapies get nod
Clinical trial data disappoint Amgen investors
Amgen says that a new trial of its anemia drug Aranesp indicated a higher risk of death among patients with anemia caused by cancer. Aranesp is currently approved to treat anemia caused by chemotherapy and Amgen has been looking to broaden its approval for the drug. The new data raises new questions about the risks posed by Aranesp as well as two similar drugs--Epogen and Procrit--with a …
Read more...Erbitux data backs use as front-line therapy
Researchers announced that Erbitux proved effective as a front-line therapy against colon cancer, a big development for a therapy that is currently approved only after the unsuccessful use of chemotherapy. Data indicates that Erbitux delays progression of the disease when given as a combinational therapy with chemotherapy. That's good news for Bristol-Myers Squibb and ImClone, which share the revenue from the drug. Merck KGaA is ImClone's partner outside of the U.S. All three have been …
Read more...ALSO NOTED: Santarus inks licensing deal; NeurogesX reports positive data; and much more...
> San Diego-based Santarus will gain $15 million up front and up to $65 million in milestones in a licensing deal with Schering-Plough for a low-dose version of the heartburn drug Zegerid. Report
> NeurogesX announced positive results from a Phase III trial of Transacin (NGX-4010), a high-concentration trans-capsaicin dermal …
Read more...FDA approves Avastin for lung cancer
As expected, the FDA has approved Genentech's Avastin as a front line therapy for the most common kind of lung cancer. Some 162,000 Americans die every year from lung cancer. Avastin, already approved for colon cancer, will be provided to qualified patients for a discounted price of $55,000 a year, but only for approved indications. Genentech and other drug developers have been harshly criticized for demanding astronomically high retail prices on new therapies.
- read the AP report on the approval
Gene therapy cures two of advanced melanoma
Scientists at the National Cancer Institute are heralding what they call the first successful gene therapy experiment in cancer after curing two men with advanced melanoma. Genetically altered immune cells wiped out all signs of the cancer in the two men, though they did not help 15 other volunteers in the experiment. This is the first time, they say, that gene therapy for cancer has worked at an advanced stage of the lethal disease. And new gene therapy trials are being planned for …
Read more...Get more colon cancer coverage at:
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends

